Ascentage Pharma Group International - Unsponsored ADR (
NASDAQ:AAPG -
Get Free Report) shares dropped 5.7% on Monday . The stock traded as low as $44.23 and last traded at $45.16. Approximately 4,014 shares traded hands during trading, a decline of 90% from the average daily volume of 40,053 shares. The stock had previously closed at $47.90.
Ascentage Pharma Group International Price Performance
The stock's fifty day simple moving average is $40.17 and its 200-day simple moving average is $28.49. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53.
Institutional Trading of Ascentage Pharma Group International
A number of institutional investors have recently bought and sold shares of the company. Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International during the second quarter worth about $391,000. Tema Etfs LLC purchased a new position in shares of Ascentage Pharma Group International during the 2nd quarter worth approximately $610,000. Chevy Chase Trust Holdings LLC acquired a new position in shares of Ascentage Pharma Group International during the 2nd quarter worth approximately $227,000. Finally, Monashee Investment Management LLC purchased a new stake in Ascentage Pharma Group International in the 1st quarter valued at approximately $3,511,000.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access